Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90048


Goal is to prospectively determine if stool calprotectin and change in bowel wall thickness and hyperemia, as seen on small bowel ultrasound, at week 0, 14, and 54 can be used to predict response at week 54 to infliximab in pediatric patients with small bowel Crohn's Disease.

Study summary:

We will examine whether non-invasive disease monitoring tools such as bowel wall thickness as measured by small bowel ultrasound (SBUS) and mucosal inflammation as measured by fecal calprotectin, are independently associated with infliximab durability.


Inclusion Criteria: - Age 6-23 years - Initiating Infliximab therapy - Crohns disease involving the distal small bowel +/- proximal colon - Willingness to undergo SBUS and fecal calprotectin collection prior to starting infliximab and again at week 14 and week 54 - Able to give consent by patient and/or legal guardian Exclusion Criteria: - Ulcerative colitis or non-Crohn's Disease patients - Lack of small bowel disease - Patients started on alternative therapy - Unable or unwilling to provide consent



Primary Contact:

Principal Investigator
Namita Singh, MD
Cedars-Sinai Medical Center

Backup Contact:


Location Contact:

Los Angeles, California 90048
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.